Healthcare / Medical DevicesKOSDAQ
$3825.00
-45.00 (-1.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-4.6B · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$56.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-48.4%
↓Gross Margin
38.4%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.1%
FCF CAGR
—
FCF margin
-27.7%
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.70B · net income $-10.74B · FCF $-7.11B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.70B | $25.70B | $33.04B | $34.35B | $30.05B |
| Net Income | $-10.74B | $-10.74B | $-783.3M | $16.8M | $2.82B |
| EBITDA | $-10.19B | $-10.19B | $2.00B | $1.63B | $3.88B |
| EPS | -818.77 | -818.77 | -135.23 | 1.85 | 1808.90 |
| Gross Margin | 38.4% | 38.4% | 44.0% | 45.6% | 43.7% |
| Operating Margin | -46.9% | -46.9% | -0.6% | 13.0% | 8.4% |
| Net Margin | -41.8% | -41.8% | -2.4% | 0.0% | 9.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.35 | 0.34 | 0.62 |
| Current Ratio | 2.19 | 2.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.11B | $-7.11B | $-4.55B | $-467.6M | $508.8M |
| Returns | |||||
| ROE | -48.4% | -48.4% | -2.6% | 0.1% | 23.4% |
| Valuation | |||||
| EV/EBITDA | — | — | 19.02 | — | — |
| P/B | 2.26 | 2.26 | 1.10 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -22.2% | -22.2% | -3.8% | 14.3% | — |
| EPS Growth | -505.5% | -505.5% | -7400.0% | -99.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-52.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-135.23 → -818.77
Residual
-52.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.